329 related articles for article (PubMed ID: 36942294)
1. Drug-disease interaction: Clinical consequences of inflammation on drugs action and disposition.
Abdallah YEH; Chahal S; Jamali F; Mahmoud SH
J Pharm Pharm Sci; 2023; 26():11137. PubMed ID: 36942294
[TBL] [Abstract][Full Text] [Related]
2. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
Keating GM; Perry CM
BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
[TBL] [Abstract][Full Text] [Related]
3. Systemic Molecular Mediators of Inflammation Differentiate Between Crohn's Disease and Ulcerative Colitis, Implicating Threshold Levels of IL-10 and Relative Ratios of Pro-inflammatory Cytokines in Therapy.
Kiernan MG; Coffey JC; Sahebally SM; Tibbitts P; Lyons EM; O'leary E; Owolabi F; Dunne CP
J Crohns Colitis; 2020 Jan; 14(1):118-129. PubMed ID: 31241755
[TBL] [Abstract][Full Text] [Related]
4. Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation.
Tikhonova IA; Yang H; Bello S; Salmon A; Robinson S; Hemami MR; Dodman S; Kharechko A; Haigh RC; Jani M; McDonald TJ; Hoyle M
Health Technol Assess; 2021 Feb; 25(8):1-248. PubMed ID: 33555998
[TBL] [Abstract][Full Text] [Related]
5. The roles of small-molecule inflammatory mediators in rheumatoid arthritis.
Cheng Q; Wu H; Du Y
Scand J Immunol; 2021 Mar; 93(3):e12982. PubMed ID: 33025632
[TBL] [Abstract][Full Text] [Related]
6. Periodontal Disease as a Risk Factor for Rheumatoid Arthritis: A Systematic Review.
Kaur S; White S; Bartold M
JBI Libr Syst Rev; 2012; 10(42 Suppl):1-12. PubMed ID: 27820156
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
Niederau C; Backmerhoff F; Schumacher B; Niederau C
Hepatogastroenterology; 1997; 44(13):90-107. PubMed ID: 9058126
[TBL] [Abstract][Full Text] [Related]
8. Drug-disease interactions: reduced beta-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat.
Kulmatycki KM; Abouchehade K; Sattari S; Jamali F
Br J Pharmacol; 2001 May; 133(2):286-94. PubMed ID: 11350865
[TBL] [Abstract][Full Text] [Related]
9. Drug disposition in pathophysiological conditions.
Gandhi A; Moorthy B; Ghose R
Curr Drug Metab; 2012 Nov; 13(9):1327-44. PubMed ID: 22746301
[TBL] [Abstract][Full Text] [Related]
10. [Cytokines in rheumatoid arthritis: new therapeutic possibilities].
Szekanecz Z; Szegedi G
Orv Hetil; 1998 Apr; 139(14):819-23. PubMed ID: 9569729
[TBL] [Abstract][Full Text] [Related]
11. CYP-derived eicosanoids: Implications for rheumatoid arthritis.
Hoxha M; Zappacosta B
Prostaglandins Other Lipid Mediat; 2020 Feb; 146():106405. PubMed ID: 31838196
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory molecules: a target for treatment of systemic autoimmune diseases.
Tincani A; Andreoli L; Bazzani C; Bosisio D; Sozzani S
Autoimmun Rev; 2007 Nov; 7(1):1-7. PubMed ID: 17967717
[TBL] [Abstract][Full Text] [Related]
13. Inflammation Suppresses Patients' Ability to Metabolize Cytochrome P450 Substrate Drugs.
White CM
Ann Pharmacother; 2022 Jul; 56(7):809-819. PubMed ID: 34590872
[TBL] [Abstract][Full Text] [Related]
14. Systems model identifies baseline cytokine concentrations as potential predictors of rheumatoid arthritis inflammatory response to biologics.
Nakada T; Mager DE
Br J Pharmacol; 2022 Aug; 179(16):4063-4077. PubMed ID: 35355255
[TBL] [Abstract][Full Text] [Related]
15. In vitro effects of 2 antirheumatic drugs on the synthesis and expression of proinflammatory cytokines in synovial membranes from patients with rheumatoid arthritis.
Ounissi-Benkalha H; Pelletier JP; Tardif G; Mineau F; Jolicoeur FC; Ranger P; Martel-Pelletier J
J Rheumatol; 1996 Jan; 23(1):16-23. PubMed ID: 8838503
[TBL] [Abstract][Full Text] [Related]
16. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE).
Bondeson J; Maini RN
Int J Clin Pract; 2001 Apr; 55(3):211-6. PubMed ID: 11351775
[TBL] [Abstract][Full Text] [Related]
17. Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease.
Boutet MA; Bart G; Penhoat M; Amiaud J; Brulin B; Charrier C; Morel F; Lecron JC; Rolli-Derkinderen M; Bourreille A; Vigne S; Gabay C; Palmer G; Le Goff B; Blanchard F
Clin Exp Immunol; 2016 May; 184(2):159-73. PubMed ID: 26701127
[TBL] [Abstract][Full Text] [Related]
18. Resolution of chronic inflammatory disease: universal and tissue-specific concepts.
Schett G; Neurath MF
Nat Commun; 2018 Aug; 9(1):3261. PubMed ID: 30111884
[TBL] [Abstract][Full Text] [Related]
19. Potential Effects of COVID-19 on Cytochrome P450-Mediated Drug Metabolism and Disposition in Infected Patients.
Deb S; Arrighi S
Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):185-203. PubMed ID: 33538960
[TBL] [Abstract][Full Text] [Related]
20. Tinospora cordifolia inhibits autoimmune arthritis by regulating key immune mediators of inflammation and bone damage.
Sannegowda KM; Venkatesha SH; Moudgil KD
Int J Immunopathol Pharmacol; 2015 Dec; 28(4):521-31. PubMed ID: 26467057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
